Posted on February 15, 2019 by Sitemaster
On Thursday, here in San Francisco, Dr. Andrew Armstrong first presented the results of the so-called ARCHES trial of enzalutamide (Xtandi) + standard androgen deprivation therapy (ADT) in the treatment of men with metastatic, “hormone-sensitive” prostate cancer (mHSPC). … READ MORE …
Filed under: Uncategorized | Tagged: ADT, ARCHES, enzalutamide, hormone-sensitive, metastatic, mHSPC, Xtandi | 4 Comments »
Posted on December 20, 2018 by Sitemaster
Pfizer and Astellas have, this morning, announced that the addition of enzalutamide to standard androgen deprivation (ADT) has led to improved outcomes in men with metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, ARCHES, deprivation, enzalutamide, hormone, outcome, sensitive, standard, trial | 2 Comments »
Posted on November 8, 2018 by Sitemaster
We have long been bedeviled by questions about some of the short- and the long-term side effects and complications of androgen deprivation therapy (ADT) in the treatment of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, Alzheimer's, androgen, dementia, deprivation, failure, heart, side effect | 2 Comments »
Posted on October 21, 2018 by Sitemaster
New data from the ongoing STAMPEDE trial in the UK and Switzerland has now confirmed that ablative radiation of the prostate itself (debulking of the primary tumor) improves overall survival (OS) in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden but not in those with higher burden of disease. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, debulking, deprivation, docetaxel, metastasis, primary, radiation, therapy, tumor | 7 Comments »
Posted on October 17, 2018 by Sitemaster
Three new articles in the Journal of Oncology Practice take close look at the issue of risk/benefit and “value” in the management of prostate cancer today — and the management of advanced disease in particular. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, cardiocascular, cost, deprivation, effect, metabolic, outcome, sie, value | 7 Comments »
Posted on October 8, 2018 by Sitemaster
Most men who are taking androgen deprivation therapy (ADT) for metastatic prostate cancer feel the need to “do something” about their diet in order to (a) further help to control the risk for progression of their cancer and (b) help to cope with the side effects of ADT. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: ADT, adverse, androgen, deprivation, diet, effects, nutrition, side | 3 Comments »
Posted on September 10, 2018 by Sitemaster
A newly published article in the Journal of Urology has indicated risk of an association between treatment with androgen deprivation therapy (ADT) and risk for a spectrum of liver disorders. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, adverse, andogen, deprivation, disease, effect, fatty, liver, NAFLD, nonalcoholic | 4 Comments »
